BOSTON, Sept. 14, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical firm centered on reworking the lives of sufferers and their households dwelling with hyperphagia and extreme weight problems brought on by uncommon melanocortin-4 receptor pathway (MC4R) ailments, at present introduced the pricing of its public providing of 4,800,000 shares of its frequent inventory at a public providing value of $26.00 per share. All of the shares are being supplied by Rhythm. In addition, Rhythm has granted the underwriters a 30-day choice to buy as much as a further 720,000 shares of its frequent inventory on the public providing value, much less the underwriting low cost and fee. The providing is predicted to shut on September 19, 2022, topic to the satisfaction of customary closing circumstances.
Cowen, Stifel and Wells Fargo Securities are performing as joint book-running managers for the providing. Ladenburg Thalmann is performing as supervisor for the providing.
The providing is being made pursuant to a shelf registration assertion on Form S-3, together with a base prospectus, that was filed by Rhythm with the Securities and Exchange Commission (“SEC”) on November 2, 2021 and declared efficient by the SEC on November 15, 2021. A preliminary prospectus complement regarding the providing was filed with the SEC on September 14, 2022. The ultimate prospectus complement regarding the providing can be filed with the SEC. Copies of the ultimate prospectus complement regarding the providing, when obtainable, could also be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by phone at (833) 297-2926 or by e mail at [email protected]; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by phone at 415-364-2720 or by e mail at [email protected], or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West thirty third Street, New York, New York 10001, at 833-690-2713 or e mail a request to [email protected].
This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase, nor shall there be any sale of these securities in any state or jurisdiction during which such a proposal, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.
Forward Looking Statement
This press launch incorporates forward-looking statements inside the which means of the Private Securities Litigation Reform Act of 1995. All statements contained on this press launch that don’t relate to issues of historic truth ought to be thought of forward-looking statements, together with with out limitation statements concerning the completion of the general public providing. Statements utilizing phrases comparable to “expect”, “anticipate”, “believe”, “may”, “will” and comparable phrases are additionally forward-looking statements. Such statements are topic to quite a few dangers and uncertainties, together with, however not restricted to, dangers related to normal financial and market circumstances and the opposite essential components mentioned beneath the caption “Risk Factors” within the prospectus complement associated to the providing, our Quarterly Report on Form 10-Q for the quarterly interval ended June 30, 2022 and our different filings with the SEC. Except as required by regulation, we undertake no obligations to make any revisions to the forward-looking statements contained on this press launch or to replace them to mirror occasions or circumstances occurring after the date of this press launch, whether or not consequently of new info, future developments or in any other case.
Company Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
[email protected]
Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]
